LEADER 06019nam 22005655 450 001 9910373940303321 005 20200705150424.0 010 $a981-329-705-0 024 7 $a10.1007/978-981-32-9705-0 035 $a(CKB)4100000010122134 035 $a(DE-He213)978-981-32-9705-0 035 $a(MiAaPQ)EBC6032972 035 $a(PPN)24284913X 035 $a(EXLCZ)994100000010122134 100 $a20200130d2020 u| 0 101 0 $aeng 135 $aurnn|008mamaa 181 $ctxt$2rdacontent 182 $cc$2rdamedia 183 $acr$2rdacarrier 200 10$aAnxiety Disorders$b[electronic resource] $eRethinking and Understanding Recent Discoveries /$fedited by Yong-Ku Kim 205 $a1st ed. 2020. 210 1$aSingapore :$cSpringer Singapore :$cImprint: Springer,$d2020. 215 $a1 online resource (VII, 576 p. 32 illus., 25 illus. in color.) 225 1 $aAdvances in Experimental Medicine and Biology,$x0065-2598 ;$v1191 311 $a981-329-704-2 327 $aPart 1. Brain network concepts -- Chapter 1. Task MRI-based functional brain network of anxiety -- Chapter 2. Phenotype network and brain structural covariance network of anxiety -- Chapter 3. linear/nonlinear micro-and-macro state EEG-based functional networks for anxiety -- Chapter 4. White matter-based structural brain network of anxiety -- Chapter 5. Resting state abnormalities in anxiety disorders and spatiotemporal psychopathology -- Part 2. Neurobiological Aspects -- Chapter 6. Gene-environmental interactions and role of epigenetics in anxiety disorders -- Chapter 7. The role of the oxytocin system in anxiety disorders -- Chapter 8. Translational studies in the complex roles of neurotransmitter systems in anxiety and anxiety disorders -- Chapter 9. The role of early life stress in HPA axis dysfunction in anxiety disorders -- Chapter 10. Immune-kynurenine pathways and the gut-microbiota-brain axis in anxiety disorders -- Chapter 11. Experimental anxiety model for anxiety disorders: relevance to drug discovery -- Part 3. Diagnostic and clinical Issues -- Chapter 12. Anxiety disorders in DSM-5: changes, controversies, and future directions -- Chapter 13. Biological markers to differentiate the type of anxiety disorders -- Chapter 14. Comorbid anxiety and depression: clinical and conceptual consideration, transdiagnostic treatment -- Chapter 15. Anxiety disorders and medical comorbidity: treatment implications -- Part 4. Therapeutic Issues -- Chapter 16. Biofeedback and Neurofeedback for Anxiety Disorders: A Quantitative and Qualitative Systematic Review -- Chapter 17. Cognitive Behavioral Therapy, Mindfulness-Based Cognitive Therapy and Acceptance Commitment Therapy for Anxiety Disorders: Integrating Traditional with Digital Treatment Approaches -- Chapter 18. Neurostimulation in anxiety disorders, post-traumatic stress disorder and obsessive-compulsive disorder -- Chapter 19. Current and novel psychopharmacological drugs for anxiety disorders -- Chapter 20. Role of benzodiazepines in anxiety disorders -- Chapter 21. Virtual Reality for Anxiety Disorders: Rethinking a Field in Expansion -- Chapter 22. Current research on complementary and alternative medicine (CAM) in the treatments of anxiety disorders: evidence based review -- Chapter 23. Contemporary Psychodynamic Approaches to Treating Anxiety: Theory, Research, and Practice -- Chapter 24. Well-being therapy in anxiety disorders -- Part 5. Anxiety and precision psychiatry -- Chapter 25. Personalized clinical approaches to anxiety disorders -- Chapter 26. The role of hormonal and reproductive status in the treatment of anxiety disorders in women -- Chapter 27. Risk factors and prevention strategies for anxiety disorders in childhood and adolescence -- Chapter 28. Anxiety disorders in the elderly. 330 $aThis book reviews all important aspects of anxiety disorders with the aim of shedding new light on these disorders through combined understanding of traditional and novel paradigms. The book is divided into five sections, the first of which reinterprets anxiety from a network science perspective, examining the altered topological properties of brain networks in anxiety disorders. The second section discusses recent advances in understanding of the neurobiology of anxiety disorders, covering, for example, gene-environmental interactions and the roles of neurotransmitter systems and the oxytocin system. A wide range of diagnostic and clinical issues in anxiety disorders are then addressed, before turning attention to contemporary treatment approaches in the context of novel bio-psychosocial-behavioral models, including bio- and neurofeedback, cognitive behavioral therapy, neurostimulation, virtual reality exposure therapy, pharmacological interventions, psychodynamic therapy, and CAM options. The final section is devoted to precision psychiatry in anxiety disorders, an increasingly important area as we move toward personalized treatment. Anxiety Disorders will be of interest for all researchers and clinicians in the field. 410 0$aAdvances in Experimental Medicine and Biology,$x0065-2598 ;$v1191 606 $aNeurosciences 606 $aNeurobiology 606 $aNeuropsychology 606 $aNeurosciences$3https://scigraph.springernature.com/ontologies/product-market-codes/B18006 606 $aNeurobiology$3https://scigraph.springernature.com/ontologies/product-market-codes/L25066 606 $aNeuropsychology$3https://scigraph.springernature.com/ontologies/product-market-codes/Y12030 615 0$aNeurosciences. 615 0$aNeurobiology. 615 0$aNeuropsychology. 615 14$aNeurosciences. 615 24$aNeurobiology. 615 24$aNeuropsychology. 676 $a616.8522 702 $aKim$b Yong-Ku$4edt$4http://id.loc.gov/vocabulary/relators/edt 801 0$bMiAaPQ 801 1$bMiAaPQ 801 2$bMiAaPQ 906 $aBOOK 912 $a9910373940303321 996 $aAnxiety Disorders$91910040 997 $aUNINA